British research shows that the COVID-19 vaccine reduces the risk of cardiovascular complications

Almost as soon as the COVID-19 pandemic broke out, the ruling class campaigned vigorously against any measures that, while fighting the virus, could hinder their ability to accumulate profits.

The world’s governments quickly adopted a vaccine-only strategy, pushing aside other public health measures. This has now largely been replaced by a total ‘let it rip’ policy, as even vaccines become more difficult to access, for the populations that once had access to them in large numbers.

In this Thursday, April 29, 2021 photo, Sherry Cross Child, a Canadian resident of Stand Off, Alberta, receives a COVID-19 vaccine at the Piegan-Carway border crossing near Babb, Mont. (AP Photo/Iris Samuels)

To justify this destructive course of action, information about the virus has been withheld or misrepresented, and various pseudoscientific claims have been made to downplay the severity of the disease. This has created a fertile environment for backward anti-vaccine views and conspiracy theories, which are openly supported by some of the most deranged sections of the ruling class.

One of the arguments most often cited by “anti-vaxers” is the existence of some cases in which people developed cardiovascular complications after vaccination – a small number of which resulted in the tragic deaths of the vaccinated individuals. They argue that the possibility of said complications justifies rejection of the vaccine, thereby minimizing or negating the vaccine’s benefits in preventing COVID-19, a serious disease with a significant mortality rate and very well-documented, life-altering long-term consequences term. .

A study published in the journal Nature communication refutes this claim by analyzing the incidence of cardiovascular complications in a very large population of vaccinated individuals.

Research led by the Universities of Cambridge, Bristol and Edinburgh – and powered by Health Data Research UK’s British Heart Foundation (BHF) Data Science Center – analyzed anonymised health records from 46 million adults in England between December 8, 2020 and January 23, 2022.

Data scientists compared the incidence of cardiovascular disease after vaccination with the incidence before or without vaccination, during the first two years of the vaccination program. They specifically evaluated the incidence of cardiovascular and thrombotic events after the first, second and booster doses of COVID-19 vaccines from December 2020 to January 2022. The vaccines studied included the mRNA vaccines (Pfizer’s BNT-162b2 and Moderna’s mRNA-1273) and the adenovirus-based ChAdOx1 vaccine (AstraZeneca).

The study used Cox regression models to calculate adjusted hazard ratios (aHRs), which compare the risk of cardiovascular events after vaccination with the risk before or without vaccination. Across all doses and vaccine types, the incidence of thrombotic events (e.g. blood clots) was lower after vaccination, for both arterial and venous events. The reduction was already visible after the first dose, with a 10 percent lower risk of arterial thrombotic events after receiving the first dose of the Pfizer vaccine.

Across all vaccine brands, an even more substantial reduction in cardiovascular events was observed after the second dose. For example, there was a 27 percent lower risk of arterial thrombotic events after the second dose of AstraZeneca’s ChAdOx1. The AHRs for other conditions such as pulmonary embolism and deep venous thrombosis were also reduced.

Similar trends were observed for booster doses, keeping event rates lower than before vaccination. The study found that the reduction in cardiovascular events was most pronounced in the weeks immediately following vaccination.

Both mRNA vaccines (Pfizer and Moderna) and the adenovirus-based AstraZeneca vaccine showed a reduction in arterial and venous events. However, the magnitude of risk reduction varied somewhat by brand and dose, with mRNA vaccines showing slightly lower aHRs overall, especially after booster doses.

Although reductions were still visible up to 24 weeks after vaccination, the extent of reduction decreased over time.

Previous research has shown that the incidence of rare cardiovascular complications is higher after some COVID-19 vaccines. This study supports these findings, but more importantly, it has identified no new adverse cardiovascular conditions associated with COVID-19 vaccination and provides further reassurance that the benefits of vaccination outweigh the risks.

These unusual complications fall into two categories: vaccine-induced thrombotic thrombocytopenia (VITT) with AstraZeneca’s vaccine, and myocarditis and pericarditis with mRNA vaccines (Pfizer and Moderna).

VITT is a rare condition characterized by blood clots associated with low platelet counts. It can lead to serious complications, such as intracranial venous thrombosis (ICVT), which affects the blood vessels in the brain. The study found that the incidence of VITT was higher than normal after the first dose of the AstraZeneca vaccine, with the highest risk occurring within the first two weeks after vaccination.

No increased risk of VITT was observed after the second dose of ChAdOx1 or after a dose of mRNA vaccines, indicating that the risk is mainly associated with the first dose of the AstraZeneca vaccine.

Myocarditis is an inflammation of the heart muscle, while pericarditis is an inflammation of the lining around the heart. Both conditions can cause chest pain, fatigue, and other heart symptoms, but are often mild and self-limiting. The increased risk of both myocarditis and pericarditis was highest in the first week after vaccination for both the Pfizer and Moderna vaccines, with the risk generally returning to baseline levels within four weeks after vaccination.

Although rare complications have been associated with COVID-19 vaccines, they were mainly related to the first dose and typically occurred within the first weeks after vaccination. The study highlights that these risks, while present, are outweighed by the broader protective benefits of vaccination against COVID-19 and associated cardiovascular risks.

A major strength of the study is the significant number of people studied, which allowed the researchers to assess the effects of the vaccines across a wide variety of demographic and clinical subgroups, such as age, gender, ethnicity and previous health conditions. The broad reduction in thrombotic events was observed in all subgroups, reinforcing the value of the vaccines in preventing COVID-19-related cardiovascular complications.

The effects of the vaccines were especially effective in older adults (over 40 years), for whom the risk of rare complications such as myocarditis was significantly lower, while the benefits in terms of reduced cardiovascular events were even more pronounced.

Co-lead author Dr. Samantha Ip, Research Associate at the Department of Health and Primary Care, University of Cambridge, told Health Data Research UK: “This study further supports the body of evidence on the safety of the COVID-19 vaccination. program, which has been shown to protect against severe COVID-19 and has saved millions of lives worldwide.”

Professor William Whiteley, Associate Director at the BHF Data Science Center and Professor of Neurology and Epidemiology at the University of Edinburgh, added that the study “demonstrates that the benefits of second and booster doses, with less common cardiovascular events including heart attacks and include strokes. vaccination, outweigh the very rare cardiovascular complications.”

The results demonstrate the enormous potential of society’s creative and productive forces. Although vaccines are an important tool in the fight against the pandemic, they are not sufficient on their own. Without a policy of complete elimination of the virus through a comprehensive regime of testing, tracing and quarantine, a vaccination program amounts to mere palliative care.

This can currently be seen in the UK’s autumn vaccination booster campaign. Firstly, the vast majority of people are no longer eligible for a free vaccine through the National Health Service and must pay for it privately. While the NHS is offering free vaccines to old and clinically vulnerable people, the vaccines available are designed for KP or even older variants of the virus.

The XEC variant currently causing a new wave of infections is expected to become dominant. It is unclear exactly how effective the current boosters are against this, but experience shows that they will not be as effective as against the variant for which they were designed. The virus’s ability to mutate and thus evade the protection provided by vaccines or previous infections is greatly helped by the fact that COVID-19 has been allowed to roam society unhindered after key mitigation measures were all in place as early as March 2022 cancelled.

Related Posts

ROSEN, TRUSTED INVESTOR ADVISOR, encourages Indivior PLC investors to engage counsel in securities class action ahead of key deadline – INDV Page 1

Eine Leber aus Licht – winstschaft.de

Menschen mit Organizationstalent erobern die Welt